While the Affordable Care Act (ACA) provides the opportunity for the Secretary of Health and Human Services (HHS) to periodically review the definition of Essential Health Benefits (EHBs), we caution HHS from making any changes or developing any new framework that would reduce the level of prescription drug coverage for beneficiaries. We believe that the current framework and requirements governing prescription drugs that are based on benchmark plans and allow states to add additional benefits are generally working well for patients. Our biggest concerns are the lack of adequate prescription drug coverage, the lack of enforcement of all EHB regulations, and allowing insurers and pharmacy benefit managers (PBMs) to skirt the EHB law and regulations. Below are our recommendations to strengthen prescription drug coverage and enforcement of existing EHB protections.
Letter to Congressman Craig Goldman supporting the Prior Authorization Accountability Act
We write to express our strong support for the Prior Authorization Accountability Act (H.R. 9396), which recently passed the Subcommittee on Health on a bipartisan basis. We thank you for your leadership in advancing meaningful transparency in the prior authorization process and urge Congress to swiftly pass this important legislation. For patients living with HIV, viral hepatitis, and other serious chronic conditions, prior authorization is too often an unnecessary barrier to timely, medically appropriate care. While our organization believes prior authorization should be significantly reduced across the healthcare system, greater transparency is an essential step toward accountability and reform.
Letter to Massachusetts Governor Healey Supporting FY27 PrEP Coverage Provisions
We write in strong support of the HIV pre-exposure prophylaxis (PrEP) coverage provisions included in the Fiscal Year 2027 budget and respectfully urge you to approve these critical provisions in their entirety.
Letter to Delaware Governor Meyer in Support of Preserving PrEP and PEP Access
The HIV+Hepatitis Policy Institute is a national organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We write in strong support of House Substitute 1 for House Bill 200 and respectfully urge you to sign this critical legislation into law. This bill protects Delawareans at risk of HIV by preserving access to highly effective pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications and related services without cost-sharing, prior authorization, or step therapy barriers.
Letter to House Ways and Means Committee supporting HR9504’s 340B transparency provisions
The 340B program is essential to HIV prevention and treatment. It was created to help safety-net providers, including HIV and STD clinics, stretch limited resources in order to serve more low-income and uninsured patients. We strongly support preserving the program so that care can be delivered to those who otherwise would be out of reach.